HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer

Breast cancer is the leading cause of cancer death in women. Hormone‐receptor‐positive breast cancer (HR + BC) is the most common pathological type of breast cancer, of which the main treatment method is endocrine therapy. Unfortunately, primary or acquired drug resistance greatly limits its efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Han, Wang, Jinlu, Li, Jingtong, Zhou, Xiaoping, Yin, Lei, Wang, Yiran, Gu, Yucui, Niu, Xingjian, Yang, Yue, Ji, Hongfei, Zhang, Qingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019207/
https://www.ncbi.nlm.nih.gov/pubmed/33453094
http://dx.doi.org/10.1111/cas.14813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019207/
https://www.ncbi.nlm.nih.gov/pubmed/33453094
http://dx.doi.org/10.1111/cas.14813

Ejemplares similares